ClinicalTrials.gg
Not yet recruitingNCT07116824Updated Aug 12, 2025

HB1801 Combined Treatment of HER2-positive Breast Cancer

A Phase 2 interventional study of HB1801 and Trastuzumab in HER2-positive Breast Cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Planned enrollment
109th of 248
80 · median 68
Started
2025
with 3 others
Phase 2
157 of 264
11 open now
Primary completion
2026-07
later than 9 of 25 live
Registered
259th of 264
by date

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 109th largest by planned enrollment of the 248 interventional ones that give a count, is one of 4 that started in 2025, is one of 157 in phase 2, reaches primary completion later than 9 of the 25 other live ones, and was the 259th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This study is designed to evaluate the safety and efficacy of HB1801 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic breast cancer.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in this study and sign the Form (ICF);
  • Age ≥ 18 years;
  • and/or cytologically confirmed unresectable locally recurrent or breast cancer;
  • -positive (IHC 3+, or IHC 2+ with ISH-positive);
  • No prior systemic chemotherapy and/or HER2-targeted therapy for unresectable locally recurrent or metastatic breast cancer (participants who have received ≤1 line of endocrine therapy are eligible); Participants who >12 months after completing (neo) chemotherapy or HER2-targeted therapy may be considered for enrollment;
  • (ECOG) performance status of 0-1;
  • At least one per 1.1. The measurable lesion should not have received local treatment such as radiotherapy (lesions in previously irradiated areas may be selected as target lesions if progression is confirmed). Target lesions cannot be bone-only metastases;
  • Adequate organ and bone marrow function (without transfusion or hematopoietic growth factor support within 14 days prior to testing):

    1. (ANC) ≥ 1.5 × 10\^9/L;
    2. count ≥ 100 × 10\^9/L;
    3. ≥ 90 g/L;
    4. Liver function: Total (TBIL) ≤ 1.0 × (ULN); (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (ALT/AST≤ 5 × ULN for participants with liver metastases; AST/ALT ≤ 1.5 × ULN for participants with alkaline phosphatase (ALP) > 2.5 × ULN);
    5. Renal function: ≥60 mL/min (calculated by Cockcroft-Gault formula);
    6. Coagulation: (INR) ≤ 1.5 and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (for participants receiving anticoagulation therapy, the investigator should confirm that INR and APTT are within safe and effective therapeutic ranges);
    7. (LVEF) > 50%;
  • Expected survival ≥ 3 months;
  • For women of : Negative serum pregnancy test within 7 days before randomization and agreement to use reliable during the study and for 3 months after last dose of docetaxel/HB1801 or 7 months after last dose of trastuzumab/pertuzumab (whichever is longer). For male participants with partners of childbearing potential: Agreement to use reliable contraception during the study and for 3 months after last dose of docetaxel/HB1801 or 7 months after last dose of trastuzumab/pertuzumab (whichever is longer).

Exclusion criteria

Exclusion Criteria:

  • to trastuzumab, pertuzumab, or docetaxel, or deemed by the investigator as unsuitable for treatment with HB1801, docetaxel, pertuzumab, or trastuzumab;
  • Participants with ≥ Grade 3 peripheral neuropathy at randomization;
  • Toxicities from prior anticancer therapy have not resolved to ≤ Grade 1 per v5.0 (except for alopecia, peripheral neuropathy, or laboratory abnormalities deemed non-risky by the investigator, which must be ≤ Grade 2);
  • History of decline to \< 50%, symptomatic congestive heart failure (CHF), or toxicity leading to permanent discontinuation during prior -targeted therapy;
  • Known or contraindications to (including but not limited to active peptic ulcer, severe hypertension, severe hypokalemia, glaucoma, etc.);
  • Prior anthracycline therapy exceeding cumulative doses of: Doxorubicin or liposomal doxorubicin > 360 mg/m², Epirubicin > 720 mg/m², Mitoxantrone > 120 mg/m², Other anthracyclines > doxorubicin-equivalent 360 mg/m²(If multiple anthracyclines were used, the total dose must not exceed 360 mg/m² doxorubicin-equivalent);
  • Use of strong inhibitors within 14 days before randomization;
  • History of hypersensitivity to any study drug component or ;
  • Untreated or unstable brain/spinal , , or cord compression (participants with treated, asymptomatic CNS lesions stable for ≥4 weeks on imaging, without edema, and off corticosteroids may be eligible);
  • Active within 3 years prior to randomization, except: studied breast cancer, locally cured tumors (e.g., resected basal/squamous skin cancer, superficial bladder cancer, cervical/breast carcinoma in situ, early-stage thyroid cancer);
  • Uncontrolled or significant cardiovascular disease, including:

    1. Class II+ CHF, unstable angina, myocardial infarction, or hemodynamically unstable arrhythmia within 6 months;
    2. Primary cardiomyopathy (e.g., dilated, hypertrophic, arrhythmogenic right ventricular, restrictive);
    3. prolongation (Fridericia-corrected QTcF > 450 ms at screening);
    4. Arterial/venous thromboembolism within 6 months (e.g., stroke, , DVT, PE);
    5. Uncontrolled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg);
  • Active/chronic infection requiring systemic antimicrobial/antiviral therapy within 14 days (including tuberculosis);
  • Active hepatitis: (HBsAg+ with HBV-DNA ≥ 2×10³ IU/mL), (anti-HCV+ with detectable HCV-RNA) *Note: HBsAg+ carriers with HBV-DNA \< 2×10³ IU/mL may enroll if willing to receive entecavir/antiviral therapy;*
  • Known infection;
  • Concurrent participation in other interventional clinical trials (except observational studies or follow-up phases) or \<4 weeks since last dose in prior interventional trials;
  • Anticancer therapy within 28 days (radiotherapy, targeted/immunotherapy, drugs) or 14 days (traditional Chinese medicine with antitumor indications);
  • Uncontrolled effusions requiring frequent drainage/medical intervention within 7 days (e.g., pleural, ascites, pericardial) or needing re-intervention within 2 weeks (excluding cytology);
  • Major surgery within 28 days (excluding );
  • Pregnant or lactating women;
  • Other conditions compromising study participation/benefit (e.g., psychiatric disorders, substance abuse, or clinically significant comorbidities).
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Cohort 1:Combination of HB1801, Trastuzumab and Pertuzumab

    HB1801: per protocol; Trastuzumab: 8mg/kg loading dose and then 6mg/kg, Q3W; Pertuzumab: 840mg loading dose and then 420mg, Q3W

    Drug: HB1801 · Drug: Trastuzumab · Drug: Pertuzumab

  • Active comparator
    Cohort 2:Combination of Docetaxel, Trastuzumab and Pertuzumab

    Docetaxel:75mg/m\^2 ,Q3W Trastuzumab: 8mg/kg loading dose and then 6mg/kg, Q3W; Pertuzumab: 840mg loading dose and then 420mg, Q3W

    Drug: Trastuzumab · Drug: Pertuzumab · Drug: Docetaxel

Interventions

  • DrugHB1801

    HB1801 is administered by intravenous infusion.

  • Trastuzumab is administered by intravenous infusion, 8mg/kg loading dose and then 6mg/kg per cycle, Q3W.

  • Pertuzumab is administered by intravenous infusion, 840mg loading dose and then 420mg per cycle, Q3W.

  • Docetaxel is administered by intravenous infusion, 75mg/m\^2, Q3W.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as assessed by RECIST 1.1

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Disease Control Rate (DCR) as assessed by RECIST 1.1

    Time frame: Up to approximately 2 years

  2. Duration of Response (DoR) as assessed by RECIST 1.1

    Time frame: Up to approximately 2 years

  3. Progression-free survival (PFS) as assessed by RECIST 1.1

    Time frame: Up to approximately 2 years

  4. Overall Survival (OS)

    Time frame: Up to approximately 2 years

  5. Incidence and severity of treatment-emergent adverse events (TEAE)

    Time frame: Up to approximately 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jul 2026, 10 months later.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 10 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 12, 2025
StartEst.
Sep 15, 2025
Primary completionEst.
Jul 15, 2026
CompletionEst.
Nov 7, 2027
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07116824
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Sep 15, 2025 (estimated)
Primary completion
Jul 15, 2026 (estimated)
Completion
Nov 7, 2027 (estimated)
Last update
Aug 12, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion